Lehigh Valley Technologies, an Allentown-based pharmaceutical company, has entered into a $4 million agreement with the government to settle claims that it schemed to avoid paying certain FDA fees, Philadelphia-area U.S. Attorney William McSwain announced Friday.

In the False Claims Act case filed in the U.S. District Court for the Eastern District of Pennsylvania, prosecutors accused the company of attempting to duck fees for new drug applications (NDA) to the Food and Drug Administration required by the Prescription Drug User Fee Act. The revenue from fees is used to fund the drug approval process.